A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor." As ...

The study, "BRAF oncogenic mutants evade autoinhibition through a common mechanism," published in Science, was conducted by co-first authors Hugo Lavoie, Ting Jin and Driss Lajoie, all of IRIC, in ...

The genes encoding IDH1/2 and BRAF are frequently altered in low-grade glioma; the presence or absence of these alterations should be determined in all patients. Maximal safe tumor resection remains ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients with advanced colorectal cancer who were treated with an epidermal growth ...

A study has disentangled the mechanisms behind one of the ways melanoma cancer cells develop resistance to treatment. The study found that, in response to some drugs, melanomas can 'break' parts of ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...